In parallel, we then arbitrarily chose to work with Nivolumab, an anti-PD-1 very frequently used in the treatment of lung cancer (more than 290 clinical trials listed on the ClinicalTrails.gov website with the “lung cancer and Nivolumab” keywords). Here, PDCD1 is linked to lung carcinoma.